Boston Scientific (BSX) Expected to Announce Quarterly Earnings on Wednesday

by · The Cerbat Gem

Boston Scientific (NYSE:BSX – Get Free Report) is expected to be announcing its Q1 2026 results before the market opens on Wednesday, April 22nd. Analysts expect the company to announce earnings of $0.7930 per share and revenue of $5.1861 billion for the quarter. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, April 22, 2026 at 8:00 AM ET.

Boston Scientific (NYSE:BSX – Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the prior year, the firm earned $0.70 earnings per share. The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. On average, analysts expect Boston Scientific to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Boston Scientific Trading Up 0.1%

Shares of BSX opened at $64.28 on Monday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. Boston Scientific has a 1-year low of $60.59 and a 1-year high of $109.50. The stock has a market cap of $95.53 billion, a price-to-earnings ratio of 33.13, a price-to-earnings-growth ratio of 0.99 and a beta of 0.78. The firm has a 50 day simple moving average of $69.60 and a 200-day simple moving average of $86.83.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.34% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Boston Scientific

Several large investors have recently added to or reduced their stakes in the business. Maverick Capital Ltd. acquired a new stake in Boston Scientific in the 4th quarter worth about $280,735,000. Farallon Capital Management LLC increased its stake in shares of Boston Scientific by 56.7% during the 4th quarter. Farallon Capital Management LLC now owns 7,439,564 shares of the medical equipment provider’s stock valued at $709,362,000 after acquiring an additional 2,693,007 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Boston Scientific by 30.7% during the 3rd quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock worth $956,680,000 after acquiring an additional 2,301,383 shares during the period. Morgan Stanley lifted its holdings in shares of Boston Scientific by 10.8% during the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after acquiring an additional 2,246,308 shares during the period. Finally, Credit Agricole S A acquired a new stake in shares of Boston Scientific in the third quarter worth approximately $204,812,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on BSX. Stifel Nicolaus lowered their target price on Boston Scientific from $110.00 to $90.00 and set a “buy” rating on the stock in a report on Friday, March 20th. Robert W. Baird reduced their price objective on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Weiss Ratings lowered Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, February 4th. National Bank Financial set a $115.00 price objective on Boston Scientific in a research report on Monday, February 2nd. Finally, Canaccord Genuity Group cut their target price on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $102.82.

Get Our Latest Analysis on BSX

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

Boston Scientific Company Profile

(Get Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.

Featured Articles